MEDIA RELEASE PR38142
Clinical Data Presented at Asia PCR/Sing LIVE Demonstrate Benefits of OrbusNeich's GenousT Bio-
engineered R stentT in Challenging Patient Subsets
HONG KONG, Feb. 2/Media OutReach-AsiaNet/--
Presentations Focus on Patients with Bifurcation Lesions and Non-ST-Segment
Elevation Acute Coronary Syndrome
OrbusNeich announced that clinical data presented at Asia PCR/Singapore LIVE 2010 demonstrated the
benefits of the Genous Bio-engineered R stent in the treatment of two challenging patient subsets.
Specifically, presentations delivered by Prof. Robbert de Winter, M.D., Ph.D., of the Academic Medical
Center (AMC) in Amsterdam and Wojciech Wojakowski, M.D., from Medical University of Silesia in Poland
focused on the use of the Genous Bio-engineered R stent in patients with bifurcation lesions and patients with
non ST-segment elevation acute coronary syndrome.
Prof. de Winter's presentation, titled "One Year Clinical Outcome after Provisional T Stenting with the
Endothelial Progenitor Cell Capturing Stent for Bifurcation Lesions," featured a single-center study with 178
patients that compared the Genous Bio-engineered R stent to a previous bare metal stent control group of 465
patients at the AMC. A 32 percent reduction of the composite of cardiac death, myocardial infarction or target
lesion revascularization was reported between these two groups. The cumulative rate of definite or probable
stent thrombosis was reduced by 57 percent in the Genous Bio-engineered R stent-treated group compared to
the control group.
"Bifurcation lesions remain a challenge for interventional cardiologists," said Prof. de Winter. "The Genous
Bio-engineered R stent, with a low rate of stent thrombosis, is an alternative for this challenging patient group."
Dr. Wojakowski presented data on the JACK-EPC trial, a comparison of the efficiency of high dose
atorvastatin and endothelial progenitor-capture stents versus bare metal stents, in the reduction of neointimal
formation in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS). The randomized
study with 60 patients compared the Genous Bio-engineered R stent with bare metal stents with concomitant
high dose atorvastatin in the reduction of neointimal hyperplasia assessed by coronary angiography and IVUS
after six months.
In the JACK-EPC trial, the Genous Bio-engineered R stent induced less neointimal hyperplasia and a lower
binary restenosis rate of 13 percent in the Genous Bio- engineered R stent, compared to 26.6 percent in the
control group. Importantly, the major adverse cardiac events (MACE) rate was reported at only 10 percent in
the Genous Bio-engineered R stent treated patient group versus 16 percent in the bare metal stent treated
group.
"In our small study, we observed a lower amount of neo-intimal proliferation with the EPC capture stent
compared to the bare metal stent control," said Wojakowski. "Good safety is indicated by comparable stent
thrombosis. We think this makes the Genous stent a very promising treatment strategy for ACS patients,
especially those with high risk of bleeding or not eligible for prolonged dual antiplatelet therapy due to allergy
to ASA or clopidogrel."
"Data from both presentations support the use of the Genous Bio-engineered R stent as an effective
treatment option in what interventional cardiologists find to be challenging cases," said Al Novak,
OrbusNeich's chairman and CEO. "We look forward to continuing to work with physicians to realize the full
potential of the Genous technology.
***
Hong Kong Media Contacts:
Iva Ng
OrbusNeich
Tel: (+852) 2802 2288
ing@orbusneich.com
Ruder Finn Asia
Yvonne Au
Ruder Finn Asia
Tel: (+852) 2201 6448
auy@ruderfinnasia.com
SOURCE: OrbusNeich
Translations:
NEWS 
